This review summarizes molecular mechanisms and therapies for hepatocellular carcinoma, indicating crucial insights for improved treatment strategies.
Hepatocellular carcinoma (HCC) is a lethal malignancy with strong ties to chronic liver diseases and metabolic risks. Its pathogenesis involves complex biological processes where disrupted tumor suppressor genes and activated oncogenes drive aberrant signaling pathways and cellular differentiation. Since most patients are diagnosed at advanced stages, only a minority qualify for curative therapies. Although significant therapeutic advances have been made, the overall prognosis remains poor, largely due to high rates of recurrence and metastasis. Therefore, a deeper understanding of HCC’s molecular mechanisms is crucial for developing effective targeted treatments. This review summarizes current insights into HCC pathogenesis and systematically elaborates on contemporary therapies, discussing their respective advantages and limitations.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: